PrognomiQ Announces Breakthrough Results for the Early Detection of Lung Cancer in Ongoing Real-World Study for Its Novel Blood TestProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and most treatable stage
UPDATE – PrognomiQ Launches ProVue Lung, a Proteomics-Based Laboratory Developed Test to Aid in the Early Detection of Lung Cancer– Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –
PrognomiQ Launches ProVue Lung, a Proteomics-Based Laboratory Developed Test to Aid in the Early Detection of Lung Cancer– Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –
PrognomiQ Appoints Joel Kaufman as Chief Financial Officer– Company Aims to Launch Early Detection Lung Cancer LDT in the First Half of 2025 –
